{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:37:55Z","timestamp":1781055475648,"version":"3.54.1"},"publisher-location":"Singapore","reference-count":149,"publisher":"Springer Nature Singapore","isbn-type":[{"value":"9789819568710","type":"print"},{"value":"9789819568727","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-981-95-6872-7_23","type":"book-chapter","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:28:25Z","timestamp":1777242505000},"page":"391-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["New Antidepressant Development in the Treatment of Depression"],"prefix":"10.1007","author":[{"given":"Alessandro","family":"Spiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Caldirola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"23_CR1","volume":"14","author":"M Abbasi","year":"2022","unstructured":"Abbasi M, Santos BP, Pereira TC, Sofia R, Monteiro NRC, Sim\u00f5es CJV et al (2022) Designing optimized drug candidates with generative adversarial network. J Cheminform 14:23","journal-title":"J Cheminform"},{"key":"23_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.coph.2013.09.016","volume":"14","author":"RC Alexander","year":"2013","unstructured":"Alexander RC, Preskorn S (2013) Clinical pharmacology in the development of new antidepressants: the challenges. Curr Opin Pharmacol 14:6\u201310","journal-title":"Curr Opin Pharmacol"},{"key":"23_CR3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and statistical manual of mental disorders, fifth edition, text revision (DSM-5-TR)","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association (2022) Diagnostic and statistical manual of mental disorders, fifth edition, text revision (DSM-5-TR). APA Publishing"},{"key":"23_CR4","first-page":"1","volume":"56","author":"H Askr","year":"2022","unstructured":"Askr H, Elgeldawi E, Aboul Ella H, Elshaier YAMM, Gomaa MM, Hassanien AE (2022) Deep learning in drug discovery: an integrative review and future challenges. Artif Intell Rev 56:1\u201339","journal-title":"Artif Intell Rev"},{"key":"23_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.2174\/1570159X17666191001142934","volume":"18","author":"KV Athira","year":"2020","unstructured":"Athira KV, Bandopadhyay S, Samudrala PK, Naidu VGM, Lahkar M, Chakravarty S (2020) An overview of the heterogeneity of major depressive disorder: current knowledge and future prospective. Curr Neuropharmacol 18:168\u2013187","journal-title":"Curr Neuropharmacol"},{"key":"23_CR6","unstructured":"Axsome Therapeutics Inc (2024) Axsome therapeutics initiates PARADIGM phase 3 trial of solriamfetol for the treatment of major depressive disorder. Axsome Therapeutics. Accessed 14 Mar 2025"},{"key":"23_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s13670-023-00389-1","volume":"12","author":"K Balaram","year":"2023","unstructured":"Balaram K, Wilkins KM, Maruca-Sullivan PE (2023) A new solution to an age-old problem: a review of ketamine and esketamine for treatment-resistant depression in late life. Curr Geriatr Rep 12:93\u2013102","journal-title":"Curr Geriatr Rep"},{"key":"23_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/10600280221091301","volume":"57","author":"KN Barnes","year":"2023","unstructured":"Barnes KN, Vogl C, Nelson LA (2023) Zuranolone: the first FDA-approved oral treatment option for postpartum depression. Ann Pharmacother 57:1\u20138","journal-title":"Ann Pharmacother"},{"key":"23_CR9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/17460441.2023.2224555","volume":"18","author":"LS Brady","year":"2023","unstructured":"Brady LS, Lisanby SH, Gordon JA (2023) New directions in psychiatric drug development: promising therapeutics in the pipeline. Expert Opin Drug Discov 18:835\u2013850","journal-title":"Expert Opin Drug Discov"},{"key":"23_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106917","volume":"196","author":"C Brandwein","year":"2023","unstructured":"Brandwein C, Leenaars CHC, Becker L, Pfeiffer N, Iorgu AM, Hahn M et al (2023) A systematic mapping review of the evolution of the rat forced swim test: protocols and outcome parameters. Pharmacol Res 196:106917","journal-title":"Pharmacol Res"},{"key":"23_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/ijnp\/pyac043","volume":"25","author":"JS Burgdorf","year":"2022","unstructured":"Burgdorf JS, Zhang XL, Stanton PK, Moskal JR, Donello JE (2022) Zelquistinel is an orally bioavailable novel NMDA receptor allosteric modulator that exhibits rapid and sustained antidepressant-like effects. Int J Neuropsychopharmacol 25:979\u2013991","journal-title":"Int J Neuropsychopharmacol"},{"key":"23_CR12","doi-asserted-by":"publisher","first-page":"7472","DOI":"10.1523\/JNEUROSCI.1384-23.2023","volume":"43","author":"LP Cameron","year":"2023","unstructured":"Cameron LP, Benetatos J, Lewis V, Bonniwell EM, Jaster AM, Moliner R et al (2023) Beyond the 5-HT2A receptor: classic and nonclassic targets in psychedelic drug action. J Neurosci 43:7472\u20137482","journal-title":"J Neurosci"},{"key":"23_CR13","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R et al (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384:1402\u20131411","journal-title":"N Engl J Med"},{"key":"23_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.513068","volume":"12","author":"VB Cavenaghi","year":"2021","unstructured":"Cavenaghi VB, da Costa LP, Lacerda ALT, Hirata ES, Miguel EC, Fraguas R (2021) Subcutaneous ketamine in depression: a systematic review. Front Psychiatry 12:513068","journal-title":"Front Psychiatry"},{"key":"23_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","volume":"181","author":"L Chang","year":"2019","unstructured":"Chang L, Zhang K, Pu Y, Qu Y, Wang S, Xiong Z et al (2019) Comparison of antidepressant and side effects in mice after intranasal administration of (R, S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacol Biochem Behav 181:53\u201359","journal-title":"Pharmacol Biochem Behav"},{"key":"23_CR16","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.drudis.2020.12.013","volume":"26","author":"Z Chen","year":"2021","unstructured":"Chen Z, Liu X, Hogan W, Shenkman E, Bian J (2021) Applications of artificial intelligence in drug development using real-world data. Drug Discov Today 26:1256\u20131264","journal-title":"Drug Discov Today"},{"key":"23_CR17","first-page":"897","volume":"97","author":"A Chowdhury","year":"2025","unstructured":"Chowdhury A, Boukezzi S, Costi S, Hameed S, Jacob Y, Salas R et al (2025) Effects of the KCNQ (Kv7) channel opener ezogabine on resting-state functional connectivity of striatal brain reward regions, depression and anhedonia in major depressive disorder: results from a randomized controlled trial. Biol Psychiatry 97:897\u2013907","journal-title":"Biol Psychiatry"},{"key":"23_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.22m14445","volume":"84","author":"AH Clayton","year":"2023","unstructured":"Clayton AH, Lasser R, Nandy I, Sankoh AJ, Jonas J, Kanes SJ (2023a) Zuranolone in major depressive disorder. J Clin Psychiatry 84:1\u201310","journal-title":"J Clin Psychiatry"},{"key":"23_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/appi.ajp.20220459","volume":"180","author":"AH Clayton","year":"2023","unstructured":"Clayton AH, Lasser R, Parikh SV, Iosifescu DV, Jung J, Kotecha M et al (2023b) Zuranolone for the treatment of adults with major depressive disorder: a randomized, placebo-controlled phase 3 trial. Am J Psychiatry 180:1\u201312","journal-title":"Am J Psychiatry"},{"key":"23_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41398-021-01286-x","volume":"11","author":"SE Cohen","year":"2021","unstructured":"Cohen SE, Zantvoord JB, Wezenberg BN, Bockting CLH, van Wingen GA (2021) Magnetic resonance imaging for individual prediction of treatment response in major depressive disorder: a systematic review and meta-analysis. Transl Psychiatry 11:377","journal-title":"Transl Psychiatry"},{"key":"23_CR21","volume-title":"Guideline on clinical investigation of medicinal products","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2023","unstructured":"Committee for Medicinal Products for Human Use (CHMP) (2023) Guideline on clinical investigation of medicinal products. EMA. Accessed 14 Mar 2025"},{"key":"23_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1176\/appi.ajp.2020.20050653","volume":"178","author":"S Costi","year":"2021","unstructured":"Costi S, Morris L, Kirkwood K, Hoch M, Corniquel M, Vo-Le B et al (2021) Impact of the KCNQ2\/3 channel opener ezogabine on reward circuit activity and clinical symptoms in depression: results from a randomized controlled trial. Am J Psychiatry 178:437\u2013446","journal-title":"Am J Psychiatry"},{"key":"23_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.24","volume":"3","author":"MG Craske","year":"2017","unstructured":"Craske MG, Stein MB, Eley TC, Milad MR, Holmes A, Rapee RM et al (2017) Anxiety disorders. Nat Rev Dis Primers 3:17024","journal-title":"Nat Rev Dis Primers"},{"key":"23_CR24","first-page":"1","volume":"9","author":"L Cui","year":"2024","unstructured":"Cui L, Li S, Wang S, Wu X, Liu Y, Yu W et al (2024) Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther 9:1\u201315","journal-title":"Signal Transduct Target Ther"},{"key":"23_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-023-02514-2","volume":"13","author":"AJ Cutler","year":"2023","unstructured":"Cutler AJ, Mattingly GW, Maletic V (2023) Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Transl Psychiatry 13:1\u201316","journal-title":"Transl Psychiatry"},{"key":"23_CR26","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","volume":"47","author":"DC D\u2019Souza","year":"2022","unstructured":"D\u2019Souza DC, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M (2022) Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology 47:1854\u20131862","journal-title":"Neuropsychopharmacology"},{"key":"23_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2020","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW et al (2020) Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatr 78:481\u2013489","journal-title":"JAMA Psychiatr"},{"key":"23_CR28","doi-asserted-by":"crossref","unstructured":"De Diego-Adeli\u00f1o J, Crespo JM, Mora F, Neyra A, Iborra P, Guti\u00e9rrez-Rojas L et al (2021) Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opin Drug Saf 21:1\u201318","DOI":"10.1080\/14740338.2022.2019705"},{"key":"23_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.119.260281","volume":"371","author":"N Dedic","year":"2019","unstructured":"Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE et al (2019) SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther 371:1\u201314","journal-title":"J Pharmacol Exp Ther"},{"key":"23_CR30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","volume":"78","author":"KM Deligiannidis","year":"2021","unstructured":"Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S et al (2021) Effect of zuranolone vs placebo in postpartum depression. JAMA Psychiatr 78:951\u2013959","journal-title":"JAMA Psychiatr"},{"key":"23_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/appi.ajp.20220785","volume":"180","author":"KM Deligiannidis","year":"2023","unstructured":"Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman MP, Lasser R et al (2023) Zuranolone for the treatment of postpartum depression. Am J Psychiatry 180:1\u201310","journal-title":"Am J Psychiatry"},{"key":"23_CR32","first-page":"1","volume":"49","author":"ZD Deng","year":"2023","unstructured":"Deng ZD, Robins PL, Regenold WT, Rohde P, Dannhauer M, Lisanby SH (2023) How electroconvulsive therapy works in the treatment of depression: is it the seizure, the electricity, or both? Neuropsychopharmacology 49:1\u201312","journal-title":"Neuropsychopharmacology"},{"key":"23_CR33","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/ijms26031082","volume":"26","author":"D Dhieb","year":"2025","unstructured":"Dhieb D, Bastaki K (2025) Pharmaco-multiomics: a new frontier in precision psychiatry. Int J Mol Sci 26:1082","journal-title":"Int J Mol Sci"},{"key":"23_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/ijnp\/pyy101","volume":"22","author":"JE Donello","year":"2018","unstructured":"Donello JE, Banerjee P, Li YX, Guo YX, Yoshitake T, Zhang XL et al (2018) Positive N-methyl-D-aspartate receptor modulation by rapastinel promotes rapid and sustained antidepressant-like effects. Int J Neuropsychopharmacol 22:247\u2013259","journal-title":"Int J Neuropsychopharmacol"},{"key":"23_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/ph18020157","volume":"18","author":"JE Donello","year":"2025","unstructured":"Donello JE, McIntyre RS, Pickel DB, Stahl SM (2025) Demystifying the antidepressant mechanism of action of stinels, a novel class of neuroplastogens: positive allosteric modulators of the NMDA receptor. Pharmaceuticals 18:157","journal-title":"Pharmaceuticals"},{"key":"23_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","volume":"102","author":"RS Duman","year":"2019","unstructured":"Duman RS, Sanacora G, Krystal JH (2019) Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron 102:75\u201390","journal-title":"Neuron"},{"key":"23_CR37","volume":"76","author":"D Erritzoe","year":"2024","unstructured":"Erritzoe D, Barba T, Greenway KT, Murphy R, Martell J, Giribaldi B et al (2024) Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. EClin Med 76:102799","journal-title":"EClin Med"},{"key":"23_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-53463-9","volume":"14","author":"PM Estave","year":"2024","unstructured":"Estave PM, Albertson SE, Karkhanis AN, Jones SR (2024) Co-targeting the kappa opioid receptor and dopamine transporter reduces motivation to self-administer cocaine and partially reverses dopamine system dysregulation. Sci Rep 14:1\u201312","journal-title":"Sci Rep"},{"key":"23_CR39","first-page":"1","volume":"1","author":"M Falchi-Carvalho","year":"2024","unstructured":"Falchi-Carvalho M, Barros H, Bolcont R, Laborde S, Wie\u00dfner I, Ruschi B et al (2024) The antidepressant effects of vaporized N,N-dimethyltryptamine: an open-label pilot trial in treatment-resistant depression. Psychedelic Med 1:1\u201312","journal-title":"Psychedelic Med"},{"key":"23_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ibror.2019.01.001","volume":"6","author":"OJ Fasipe","year":"2019","unstructured":"Fasipe OJ (2019) The emergence of new antidepressants for clinical use: agomelatine paradox versus other novel agents. IBRO Rep 6:95\u2013110","journal-title":"IBRO Rep"},{"key":"23_CR41","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00406-023-01571-4","volume":"273","author":"M Fava","year":"2023","unstructured":"Fava M, Stahl SM, De Martin S, Mattarei A, Bettini E, Comai S et al (2023) Esmethadone-HCl (REL-1017): a promising rapid antidepressant. Eur Arch Psychiatry Clin Neurosci 273:1463\u20131476","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"23_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.24m15265","volume":"85","author":"M Fava","year":"2024","unstructured":"Fava M, Stahl SM, Pani L, Martin SD, Cutler AJ, Maletic V et al (2024) Efficacy and safety of esmethadone (REL-1017) in patients with major depressive disorder and inadequate response to standard antidepressants. J Clin Psychiatry 85:1\u201312","journal-title":"J Clin Psychiatry"},{"key":"23_CR43","unstructured":"FDA (2025) Psychedelic drugs: considerations for clinical investigations; guidance for industry; draft guidance. Regulations.gov. Accessed 14 Mar 2025"},{"key":"23_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/76061","volume":"25","author":"D Filliol","year":"2000","unstructured":"Filliol D, Ghozland S, Chluba J, Martin M, Matthes HWD, Simonin F et al (2000) Mice deficient for \u03b4- and \u03bc-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195\u2013200","journal-title":"Nat Genet"},{"key":"23_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2014.00005","volume":"8","author":"TE Fitch","year":"2014","unstructured":"Fitch TE, Benvenga MJ, Jesudason CD, Zink C, Vandergriff AB, Menezes MM et al (2014) LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy. Front Neurosci 8:5","journal-title":"Front Neurosci"},{"key":"23_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","volume":"8","author":"WW Fleischhacker","year":"2021","unstructured":"Fleischhacker WW, Podhorna J, Gr\u00f6schl M, Hake S, Zhao Y, Huang S et al (2021) Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry 8:191\u2013201","journal-title":"Lancet Psychiatry"},{"key":"23_CR47","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jad.2014.10.010","volume":"172","author":"EI Fried","year":"2015","unstructured":"Fried EI, Nesse RM (2015) Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study. J Affect Disord 172:96\u2013102","journal-title":"J Affect Disord"},{"key":"23_CR48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1126\/science.1249240","volume":"344","author":"AK Friedman","year":"2014","unstructured":"Friedman AK, Walsh JJ, Juarez B, Ku SM, Chaudhury D, Wang J et al (2014) Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience. Science 344:313\u2013319","journal-title":"Science"},{"key":"23_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11671","volume":"7","author":"AK Friedman","year":"2016","unstructured":"Friedman AK, Juarez B, Ku SM, Zhang H, Calizo RC, Walsh JJ et al (2016) KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. Nat Commun 7:11671","journal-title":"Nat Commun"},{"key":"23_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pnpbp.2017.03.010","volume":"77","author":"ML Garcez","year":"2017","unstructured":"Garcez ML, Mina F, Bellettini-Santos T, Carneiro FG, Luz AP, Schiavo GL et al (2017) Minocycline reduces inflammatory parameters in the brain structures and serum and reverses memory impairment caused by the administration of amyloid \u03b2 (1-42) in mice. Prog Neuro-Psychopharmacol Biol Psychiatry 77:23\u201331","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"23_CR51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.64719\/pb.4425","volume":"52","author":"A Gasparini","year":"2022","unstructured":"Gasparini A, Callegari C, Lucca G, Bellini A, Caselli I, Ielmini M (2022) Inflammatory biomarker and response to antidepressant in major depressive disorder: a systematic review and meta-analysis. Psychopharmacol Bull 52:36\u201345","journal-title":"Psychopharmacol Bull"},{"key":"23_CR52","first-page":"1","volume":"26","author":"JJ Gattuso","year":"2022","unstructured":"Gattuso JJ, Perkins D, Ruffell S, Lawrence AJ, Hoyer D, Jacobson LH et al (2022) Default mode network modulation by psychedelics: a systematic review. Int J Neuropsychopharmacol 26:1\u201312","journal-title":"Int J Neuropsychopharmacol"},{"key":"23_CR53","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/acps.13459","volume":"146","author":"SN Ghaemi","year":"2022","unstructured":"Ghaemi SN (2022) Symptomatic versus disease-modifying effects of psychiatric drugs. Acta Psychiatr Scand 146:251\u2013257","journal-title":"Acta Psychiatr Scand"},{"key":"23_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-024-03063-x","volume":"30","author":"P Glue","year":"2024","unstructured":"Glue P, Loo C, Fam J, Lane HY, Young AH, Surman P (2024) Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nat Med 30:1\u20136","journal-title":"Nat Med"},{"key":"23_CR55","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1111\/ejn.15270","volume":"55","author":"E Gorman-Sandler","year":"2021","unstructured":"Gorman-Sandler E, Hollis F (2021) The forced swim test: giving up on behavioral despair (commentary on Molendijk & de Kloet, 2021). Eur J Neurosci 55:2832\u20132835","journal-title":"Eur J Neurosci"},{"key":"23_CR56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuropharm.2016.03.021","volume":"120","author":"VK Gribkoff","year":"2017","unstructured":"Gribkoff VK, Kaczmarek LK (2017) The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes. Neuropharmacology 120:11\u201319","journal-title":"Neuropharmacology"},{"key":"23_CR57","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/JCP.0000000000001583","volume":"42","author":"C Guidetti","year":"2022","unstructured":"Guidetti C, Serra G, Pani L, Pappagallo M, Maglio G, Trasolini M et al (2022) REL-1017 (esmethadone) may rapidly reduce dissociative symptoms in adults with major depressive disorder unresponsive to standard antidepressants. J Clin Psychopharmacol 42:503\u2013506","journal-title":"J Clin Psychopharmacol"},{"key":"23_CR58","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1056\/NEJMoa1815981","volume":"381","author":"H Gunduz-Bruce","year":"2019","unstructured":"Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ et al (2019) Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med 381:903\u2013911","journal-title":"N Engl J Med"},{"key":"23_CR59","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1037\/pha0000310","volume":"28","author":"T Hanania","year":"2020","unstructured":"Hanania T, Manfredi P, Inturrisi C, Vitolo OV (2020) The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats. Exp Clin Psychopharmacol 28:196\u2013201","journal-title":"Exp Clin Psychopharmacol"},{"key":"23_CR60","first-page":"1","volume":"48","author":"JE Hanson","year":"2023","unstructured":"Hanson JE, Yuan H, Perszyk RE, Banke TG, Xing H, Tsai MC et al (2023) Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry. Neuropsychopharmacology 48:1\u201312","journal-title":"Neuropsychopharmacology"},{"key":"23_CR61","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.30367","volume":"5","author":"J Hellmann-Regen","year":"2022","unstructured":"Hellmann-Regen J, Clemens V, Gr\u00f6zinger M, Kornhuber J, Reif A, Prvulovic D et al (2022) Effect of minocycline on depressive symptoms in patients with treatment-resistant depression. JAMA Netw Open 5:e2230367","journal-title":"JAMA Netw Open"},{"key":"23_CR62","first-page":"1","volume":"93","author":"F Holze","year":"2022","unstructured":"Holze F, Gasser P, M\u00fcller F, Dolder PC, Liechti ME (2022) Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry 93:1\u201312","journal-title":"Biol Psychiatry"},{"key":"23_CR63","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/mp.2014.185","volume":"20","author":"DT Hsu","year":"2015","unstructured":"Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Walker SJ et al (2015) It still hurts: altered opioid activity in the brain during social rejection and acceptance in major depressive disorder. Mol Psychiatry 20:193\u2013200","journal-title":"Mol Psychiatry"},{"key":"23_CR64","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1038\/s41380-023-02193-x","volume":"28","author":"YT Hu","year":"2023","unstructured":"Hu YT, Tan ZL, Hirjak D, Northoff G (2023) Brain-wide changes in excitation-inhibition balance of major depressive disorder: a systematic review of topographic patterns of GABA- and glutamatergic alterations. Mol Psychiatry 28:3257\u20133266","journal-title":"Mol Psychiatry"},{"key":"23_CR65","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.biopsych.2013.02.020","volume":"74","author":"CC Huang","year":"2013","unstructured":"Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P et al (2013) Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry 74:734\u2013741","journal-title":"Biol Psychiatry"},{"key":"23_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243057","volume":"15","author":"A Hui","year":"2020","unstructured":"Hui A (2020) Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: a systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain. PLoS One 15:e0243057","journal-title":"PLoS One"},{"key":"23_CR67","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","volume":"73","author":"A Inserra","year":"2020","unstructured":"Inserra A, De Gregorio D, Gobbi G (2020) Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev 73:202\u2013277","journal-title":"Pharmacol Rev"},{"key":"23_CR68","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41386-021-01127-x","volume":"46","author":"M Ironside","year":"2021","unstructured":"Ironside M, Moser AD, Holsen LM, Zuo CS, Du F, Perlo S et al (2021) Reductions in rostral anterior cingulate GABA are associated with stress circuitry in females with major depression: a multimodal imaging investigation. Neuropsychopharmacology 46:2188\u20132196","journal-title":"Neuropsychopharmacology"},{"key":"23_CR69","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1007\/s00213-020-05649-y","volume":"237","author":"ML Jacobson","year":"2020","unstructured":"Jacobson ML, Wulf HA, Browne CA, Lucki I (2020) The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice. Psychopharmacology 237:3715\u20133728","journal-title":"Psychopharmacology"},{"key":"23_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104800","volume":"140","author":"LA Jelen","year":"2022","unstructured":"Jelen LA, Stone JM, Young AH, Mehta MA (2022) The opioid system in depression. Neurosci Biobehav Rev 140:104800","journal-title":"Neurosci Biobehav Rev"},{"key":"23_CR71","doi-asserted-by":"crossref","unstructured":"Jelen LA, Young AH, Mehta MA (2023) Opioid mechanisms and the treatment of depression. Curr Top Behav Neurosci:67\u201399","DOI":"10.1007\/7854_2023_448"},{"key":"23_CR72","unstructured":"Johnson & Johnson (2024) Pivotal study of seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes. JNJ. Accessed 14 Mar 2025"},{"key":"23_CR73","unstructured":"Johnson & Johnson (2025) Statement on VENTURA program. JNJ. Accessed 7 Mar 2025"},{"key":"23_CR74","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/wps.20245","volume":"14","author":"S Kasper","year":"2015","unstructured":"Kasper S, Dold M (2015) Factors contributing to the increasing placebo response in antidepressant trials. World Psychiatry 14:304\u2013306","journal-title":"World Psychiatry"},{"key":"23_CR75","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/archpsyc.63.11.1199","volume":"63","author":"SE Kennedy","year":"2006","unstructured":"Kennedy SE, Koeppe RA, Young EA, Zubieta JK (2006) Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 63:1199\u20131208","journal-title":"Arch Gen Psychiatry"},{"key":"23_CR76","doi-asserted-by":"publisher","first-page":"1070522","DOI":"10.3389\/fpsyt.2022.1070522","volume":"13","author":"H Khazaie","year":"2022","unstructured":"Khazaie H, Sadeghi M, Khazaie S, Hirshkowitz M, Sharafkhaneh A (2022) Dual orexin receptor antagonists for treatment of insomnia: a systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant. Front Psych 13:1070522","journal-title":"Front Psych"},{"key":"23_CR77","first-page":"1","volume":"28","author":"T Kishi","year":"2022","unstructured":"Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y et al (2022) Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry 28:1\u201315","journal-title":"Mol Psychiatry"},{"key":"23_CR78","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41591-020-0806-7","volume":"26","author":"AD Krystal","year":"2020","unstructured":"Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J, Lisanby SH et al (2020) A randomized proof-of-mechanism trial applying the \u201cfast-fail\u201d approach to evaluating \u03ba-opioid antagonism as a treatment for anhedonia. Nat Med 26:760\u2013768","journal-title":"Nat Med"},{"key":"23_CR79","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jpsychires.2022.08.018","volume":"155","author":"AD Krystal","year":"2022","unstructured":"Krystal AD, Benca RM, Rosenberg R, Schweitzer PK, Malhotra A, Babson K et al (2022) Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression. J Psychiatr Res 155:202\u2013210","journal-title":"J Psychiatr Res"},{"key":"23_CR80","first-page":"1","volume":"49","author":"JH Krystal","year":"2023","unstructured":"Krystal JH, Kavalali ET, Monteggia LM (2023) Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology 49:1\u201312","journal-title":"Neuropsychopharmacology"},{"key":"23_CR81","first-page":"1977","volume":"11","author":"SR Kuvarzin","year":"2023","unstructured":"Kuvarzin SR, Sukhanov I, Onokhin K, Zakharov K, Gainetdinov RR (2023) Unlocking the therapeutic potential of ulotaront as a trace amine-associated receptor 1 agonist for neuropsychiatric disorders. Biomedicine 11:1977","journal-title":"Biomedicine"},{"key":"23_CR82","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jad.2023.02.151","volume":"330","author":"GC Leal","year":"2023","unstructured":"Leal GC, Souza-Marques B, Mello RP, Bandeira ID, Caliman-Fontes AT, Carneiro BA et al (2023) Arketamine as adjunctive therapy for treatment-resistant depression: a placebo-controlled pilot study. J Affect Disord 330:7\u201315","journal-title":"J Affect Disord"},{"key":"23_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/ICM.1000173","volume":"4","author":"B Lee","year":"2020","unstructured":"Lee B, Pothula S, Duman RS (2020) NMDAR modulators as rapid antidepressants: converging and distinct signaling mechanisms. Integr Clin Med 4:1\u201312","journal-title":"Integr Clin Med"},{"key":"23_CR84","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/acps.12572","volume":"134","author":"CK Loo","year":"2016","unstructured":"Loo CK, G\u00e1lvez V, O\u2019Keefe E, Mitchell PB, Hadzi-Pavlovic D, Leyden J et al (2016) Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand 134:48\u201356","journal-title":"Acta Psychiatr Scand"},{"key":"23_CR85","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/(SICI)1098-2396(199609)24:1<19::AID-SYN3>3.0.CO;2-J","volume":"24","author":"I Madar","year":"1996","unstructured":"Madar I, Lever JR, Kinter CM, Scheffel U, Ravert HT, Musachio JL et al (1996) Imaging of delta opioid receptors in human brain by N1 ([11C] methyl)naltrindole and PET. Synapse 24:19\u201328","journal-title":"Synapse"},{"key":"23_CR86","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/1570159X22666240815120244","volume":"23","author":"M Mamelak","year":"2025","unstructured":"Mamelak M (2025) Depression and the glutamate\/GABA-glutamine cycle. Curr Neuropharmacol 23:75\u201384","journal-title":"Curr Neuropharmacol"},{"key":"23_CR87","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/biology11111621","volume":"11","author":"DD Markov","year":"2022","unstructured":"Markov DD, Novosadova EV (2022) Chronic unpredictable mild stress model of depression: possible sources of poor reproducibility and latent variables. Biology 11:1621","journal-title":"Biology"},{"key":"23_CR88","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41386-019-0379-7","volume":"44","author":"D Matuskey","year":"2019","unstructured":"Matuskey D, Dias M, Naganawa M, Pittman B, Henry S, Li S et al (2019) Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers. Neuropsychopharmacology 44:1714\u20131719","journal-title":"Neuropsychopharmacology"},{"key":"23_CR89","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/sj.npp.1300872","volume":"31","author":"JP McLaughlin","year":"2005","unstructured":"McLaughlin JP, Li S, Valdez J, Chavkin TA, Chavkin C (2005) Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology 31:1241\u20131248","journal-title":"Neuropsychopharmacology"},{"key":"23_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-024-03180-8","volume":"14","author":"GC Medeiros","year":"2024","unstructured":"Medeiros GC, Demo I, Goes FS, Zarate CA, Gould TD (2024) Personalized use of ketamine and esketamine for treatment-resistant depression. Transl Psychiatry 14:1\u201312","journal-title":"Transl Psychiatry"},{"key":"23_CR91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/wps.20509","volume":"17","author":"AL Montejo","year":"2018","unstructured":"Montejo AL, Montejo L, Baldwin DS (2018) The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry 17:3\u201311","journal-title":"World Psychiatry"},{"key":"23_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.110037","volume":"257","author":"FG Morrison","year":"2024","unstructured":"Morrison FG, Van Orden LJ, Zeitz K, Kuijer EJ, Smith SL, Heal DJ et al (2024) Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse. Neuropharmacology 257:110037","journal-title":"Neuropharmacology"},{"key":"23_CR93","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1176\/appi.ajp.2021.21121204","volume":"179","author":"CB Nemeroff","year":"2022","unstructured":"Nemeroff CB (2022) Back to the future: esmethadone, the (maybe) nonopiate opiate, and depression. Am J Psychiatry 179:83\u201384","journal-title":"Am J Psychiatry"},{"key":"23_CR95","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41386-020-00948-6","volume":"46","author":"MA Nettis","year":"2021","unstructured":"Nettis MA, Lombardo G, Hastings C, Zajkowska Z, Mariani N, Nikkheslat N et al (2021) Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. Neuropsychopharmacology 46:939\u2013948","journal-title":"Neuropsychopharmacology"},{"key":"23_CR96","doi-asserted-by":"crossref","unstructured":"Neumora Therapeutics Inc (2024) Neumora therapeutics reports fourth quarter and full year 2024 financial results and provides business update. Neumora Therapeutics. Accessed 7 Mar 2025","DOI":"10.1016\/j.fopow.2025.03.013"},{"key":"23_CR97","unstructured":"Neumora Therapeutics Inc (2025) Neumora therapeutics reports data from KOASTAL-1 study of navacaprant in major depressive disorder. Neumora Therapeutics. Accessed 7 Mar 2025"},{"key":"23_CR98","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1038\/s41398-024-02911-1","volume":"14","author":"D Newby","year":"2024","unstructured":"Newby D, Taylor N, Joyce DW, Winchester LM (2024) Optimising the use of electronic medical records for large scale research in psychiatry. Transl Psychiatry 14:2911","journal-title":"Transl Psychiatry"},{"key":"23_CR99","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejphar.2012.04.040","volume":"686","author":"AT Nguyen","year":"2012","unstructured":"Nguyen AT, Marquez P, Hamid A, Kieffer B, Friedman TC, Lutfy K (2012) The rewarding action of acute cocaine is reduced in \u03b2-endorphin deficient but not in \u03bc opioid receptor knockout mice. Eur J Pharmacol 686:50\u201354","journal-title":"Eur J Pharmacol"},{"key":"23_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41380-021-01413-6","volume":"27","author":"TD Nguyen","year":"2022","unstructured":"Nguyen TD, Harder A, Xiong Y, Kowalec K, H\u00e4gg S, Cai N et al (2022) Genetic heterogeneity and subtypes of major depression. Mol Psychiatry 27:1\u20139","journal-title":"Mol Psychiatry"},{"key":"23_CR101","volume-title":"Prescription cost analysis\u2014England\u20142022\u201323","author":"NHS BSA","year":"2023","unstructured":"NHS BSA (2023) Prescription cost analysis\u2014England\u20142022\u201323. NHS BSA. Accessed 14 Mar 2025"},{"key":"23_CR102","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264\u2013355","journal-title":"Pharmacol Rev"},{"key":"23_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40345-023-00308-5","volume":"11","author":"AA Nierenberg","year":"2023","unstructured":"Nierenberg AA, Lavin PT, Javitt DC, Shelton RC, Sapko MT, Mathew SJ et al (2023) NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial. Int J Bipolar Disord 11:1\u201312","journal-title":"Int J Bipolar Disord"},{"key":"23_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.208","volume":"1","author":"M Nollet","year":"2021","unstructured":"Nollet M (2021) Models of depression: unpredictable chronic mild stress in mice. Curr Protoc 1:e208","journal-title":"Curr Protoc"},{"key":"23_CR105","unstructured":"NRx Pharmaceuticals Inc (2023) NRx pharmaceuticals reports minutes of recent U.S. Food and Drug Administration (FDA) meeting on the development of NRX-101 to treat severe bipolar depression in patients with suicidality. PR Newswire. Accessed 21 Feb 2025"},{"key":"23_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03848-y","volume":"9","author":"L Nummenmaa","year":"2018","unstructured":"Nummenmaa L, Saanijoki T, Tuominen L, Hirvonen J, Tuulari JJ, Nuutila P et al (2018) \u03bc-Opioid receptor system mediates reward processing in humans. Nat Commun 9:1500","journal-title":"Nat Commun"},{"key":"23_CR107","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/s41386-020-0725-9","volume":"45","author":"L Nummenmaa","year":"2020","unstructured":"Nummenmaa L, Karjalainen T, Isoj\u00e4rvi J, Kantonen T, Tuisku J, Kaasinen V et al (2020) Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety. Neuropsychopharmacology 45:1953\u20131959","journal-title":"Neuropsychopharmacology"},{"key":"23_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102491","volume":"69","author":"G Ostuzzi","year":"2024","unstructured":"Ostuzzi G, Gastaldon C, Tettamanti M, Cartabia M, Monti I, Aguglia A et al (2024) Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial. EClinicalMedicine 69:102491","journal-title":"EClinicalMedicine"},{"key":"23_CR109","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jpsychires.2024.08.026","volume":"178","author":"M Padhan","year":"2024","unstructured":"Padhan M, Mohapatra D, Mishra BR, Maiti R, Jena M (2024) Efficacy and safety of add-on sarcosine in patients with major depressive disorder: a randomized controlled trial. J Psychiatr Res 178:298\u2013304","journal-title":"J Psychiatr Res"},{"key":"23_CR110","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2018","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA et al (2018) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 49:655\u2013663","journal-title":"Psychol Med"},{"key":"23_CR111","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1111\/j.1460-9568.2007.05595.x","volume":"25","author":"F Papaleo","year":"2007","unstructured":"Papaleo F, Kieffer BL, Tabarin A, Contarino A (2007) Decreased motivation to eat in \u03bc-opioid receptor-deficient mice. Eur J Neurosci 25:3398\u20133405","journal-title":"Eur J Neurosci"},{"key":"23_CR112","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/children11070801","volume":"11","author":"S Pardossi","year":"2024","unstructured":"Pardossi S, Fagiolini A, Scheggi S, Cuomo A (2024) A systematic review on ketamine and esketamine for treatment-resistant depression and suicidality in adolescents: a new hope? Children 11:801","journal-title":"Children"},{"key":"23_CR113","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1017\/neu.2017.39","volume":"30","author":"VS Pereira","year":"2018","unstructured":"Pereira VS, Hiroaki-Sato VA (2018) A brief history of antidepressant drug development: from tricyclics to beyond ketamine. Acta Neuropsychiatr 30:307\u2013322","journal-title":"Acta Neuropsychiatr"},{"key":"23_CR114","volume-title":"Praxis precision medicines reports negative results from PRAX-114 phase 2\/3 monotherapy Aria study in patients with major depressive disorder","author":"Praxis Precision Medicines Inc","year":"2022","unstructured":"Praxis Precision Medicines Inc (2022) Praxis precision medicines reports negative results from PRAX-114 phase 2\/3 monotherapy Aria study in patients with major depressive disorder. Praxis Precision Medicines Inc.. Accessed 21 Feb 2025"},{"key":"23_CR115","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1192\/bjp.bp.108.051110","volume":"195","author":"J Price","year":"2009","unstructured":"Price J, Cole V, Goodwin GM (2009) Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry 195:211\u2013217","journal-title":"Br J Psychiatry"},{"key":"23_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1139273","volume":"14","author":"Y Qiu","year":"2023","unstructured":"Qiu Y, Duan A, Yin Z, Xie M, Chen Z, Sun X et al (2023) Efficacy and tolerability of minocycline in depressive patients with or without treatment-resistant: a meta-analysis of randomized controlled trials. Front Psychiatry 14:1139273","journal-title":"Front Psychiatry"},{"key":"23_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-55831-z","volume":"16","author":"SKL Quah","year":"2025","unstructured":"Quah SKL, Jo B, Geniesse C, Uddin LQ, Mumford JA, Barch DM et al (2025) A data-driven latent variable approach to validating the research domain criteria framework. Nat Commun 16:55831","journal-title":"Nat Commun"},{"key":"23_CR118","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2016.0838","volume":"73","author":"JA Quiroz","year":"2016","unstructured":"Quiroz JA, Tamburri P, Deptula D, Banken L, Beyer U, Rabbia M et al (2016) Efficacy and safety of basimglurant as adjunctive therapy for major depression. JAMA Psychiatr 73:675\u2013684","journal-title":"JAMA Psychiatr"},{"key":"23_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT et al (2023) Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 330:1\u201310","journal-title":"JAMA"},{"key":"23_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1133414","volume":"14","author":"J Reckweg","year":"2023","unstructured":"Reckweg J, van Leeuwen CJ, Henquet C, van Amelsvoort T, Theunissen EL, Mason NL et al (2023) A phase 1\/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Front Psych 14:1133414","journal-title":"Front Psych"},{"key":"23_CR121","doi-asserted-by":"publisher","first-page":"12342","DOI":"10.1038\/s41598-018-36507-9","volume":"9","author":"DJ Reis","year":"2019","unstructured":"Reis DJ, Casteen EJ, Ilardi SS (2019) The antidepressant impact of minocycline in rodents: a systematic review and meta-analysis. Sci Rep 9:12342","journal-title":"Sci Rep"},{"key":"23_CR122","first-page":"1930","volume":"21","author":"J Rema","year":"2021","unstructured":"Rema J, Novais F, Telles-Correia D (2021) Precision psychiatry: machine learning as a tool to find new pharmacological targets. Curr Top Med Chem 21:1930\u20131945","journal-title":"Curr Top Med Chem"},{"key":"23_CR123","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.3390\/molecules27092755","volume":"27","author":"X Ren","year":"2022","unstructured":"Ren X, Xiong J, Liang L, Chen Y, Zhang G (2022) The potential antidepressant action of duloxetine co-administered with the TAAR1 receptor agonist SEP-363856 in mice. Molecules 27:2755","journal-title":"Molecules"},{"key":"23_CR124","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","volume":"273","author":"H Rosenbrock","year":"2023","unstructured":"Rosenbrock H, Desch M, Wunderlich G (2023) Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci 273:1557\u20131566","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"23_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2024.02.031","volume":"95","author":"M Sanjay","year":"2024","unstructured":"Sanjay M, Cutler A, Visitacion N, Gold M, Yuan J, Aurora B (2024) Navacaprant, a novel kappa opioid receptor antagonist for major depressive disorder: a randomized placebo-controlled phase 2 trial. Biol Psychiatry 95:S10","journal-title":"Biol Psychiatry"},{"key":"23_CR126","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/ijnp\/pyab050","volume":"24","author":"A Savitz","year":"2021","unstructured":"Savitz A, Wajs E, Zhang Y, Xu H, Etropolski M, Thase ME et al (2021) Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study. Int J Neuropsychopharmacol 24:965\u2013976","journal-title":"Int J Neuropsychopharmacol"},{"key":"23_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41386-024-01862-x","volume":"49","author":"ME Schmidt","year":"2024","unstructured":"Schmidt ME, Kezic I, Popova V, Melkote R, Van P, Pemberton DJ et al (2024) Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI\/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study. Neuropsychopharmacology 49:1\u201312","journal-title":"Neuropsychopharmacology"},{"key":"23_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-022-02290-5","volume":"12","author":"M Shen","year":"2022","unstructured":"Shen M, Lv D, Liu X, Wang C (2022) ERK\/mTOR signaling may underlie the antidepressant actions of rapastinel in mice. Transl Psychiatry 12:1\u201312","journal-title":"Transl Psychiatry"},{"key":"23_CR130","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s44184-023-00038-7","volume":"2","author":"L Simmatis","year":"2023","unstructured":"Simmatis L, Russo EE, Geraci J, Harmsen IE, Samuel N (2023) Technical and clinical considerations for electroencephalography-based biomarkers for major depressive disorder. NPJ Ment Health Res 2:38","journal-title":"NPJ Ment Health Res"},{"key":"23_CR131","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00213-021-05982-w","volume":"239","author":"T Strekalova","year":"2022","unstructured":"Strekalova T, Liu YZ, Kiselev DA, Khairuddin S, Chiu JL, Lam J et al (2022) Chronic mild stress paradigm as a rat model of depression: facts, artifacts, and future perspectives. Psychopharmacology 239:663\u2013693","journal-title":"Psychopharmacology"},{"key":"23_CR132","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jocn.2021.01.005","volume":"86","author":"BA Strickland","year":"2021","unstructured":"Strickland BA, Bakhsheshian J, Emmanuel B, Amar A, Giannotta SL, Russin JJ et al (2021) Neuroprotective effect of minocycline against acute brain injury in clinical practice: a systematic review. J Clin Neurosci 86:50\u201357","journal-title":"J Clin Neurosci"},{"key":"23_CR133","unstructured":"SyneuRx (2022) Research-NMDA platform. SyneuRx. Accessed 21 Feb 2025"},{"key":"23_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.artmed.2019.101704","volume":"99","author":"AMY Tai","year":"2019","unstructured":"Tai AMY, Albuquerque A, Carmona NE, Subramanieapillai M, Cha DS, Sheko M et al (2019) Machine learning and big data: implications for disease modeling and therapeutic discovery in psychiatry. Artif Intell Med 99:101704","journal-title":"Artif Intell Med"},{"key":"23_CR135","first-page":"2056","volume":"23","author":"A Tan","year":"2018","unstructured":"Tan A, Costi S, Morris LS, Van Dam NT, Kautz M, Whitton AE et al (2018) Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. Mol Psychiatry 23:2056\u20132064","journal-title":"Mol Psychiatry"},{"key":"23_CR136","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1186\/s40814-023-01395-y","volume":"9","author":"K Tranberg","year":"2023","unstructured":"Tranberg K, Due TD, Rozing M, Brandt A, Kousgaard MB, M\u00f8ller A (2023) Challenges in reaching patients with severe mental illness for trials in general practice\u2014a convergent mixed methods study based on the SOFIA pilot trial. Pilot Feasibility Stud 9:1395","journal-title":"Pilot Feasibility Stud"},{"key":"23_CR137","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuron.2016.06.033","volume":"91","author":"R Tremblay","year":"2016","unstructured":"Tremblay R, Lee S, Rudy B (2016) GABAergic interneurons in the neocortex: from cellular properties to circuits. Neuron 91:260\u2013292","journal-title":"Neuron"},{"key":"23_CR138","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/j.drudis.2021.08.003","volume":"26","author":"ER Trunnell","year":"2021","unstructured":"Trunnell ER, Carvalho C (2021) The forced swim test has poor accuracy for identifying novel antidepressants. Drug Discov Today 26:2083\u20132090","journal-title":"Drug Discov Today"},{"key":"23_CR139","unstructured":"Tufts Center for the Study of Drug Development (2014) Cost to develop and win marketing approval for a new drug is $2.6 billion. GlobeNewswire. Accessed 14 Mar 2025"},{"key":"23_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14728214.2025.2452514","volume":"30","author":"K Valentino","year":"2025","unstructured":"Valentino K, Teopiz KM, Wong S, Zhang MC, Le GH, Choi H et al (2025) Seltorexant for major depressive disorder. Expert Opin Emerg Drugs 30:1\u201310","journal-title":"Expert Opin Emerg Drugs"},{"key":"23_CR141","first-page":"1","volume":"27","author":"IA von M\u00fccke-Heim","year":"2022","unstructured":"von M\u00fccke-Heim IA, Urbina-Trevi\u00f1o L, Bordes J, Ries C, Schmidt MV, Deussing JM (2022) Introducing a depression-like syndrome for translational neuropsychiatry: a plea for taxonomical validity and improved comparability between humans and mice. Mol Psychiatry 27:1\u201315","journal-title":"Mol Psychiatry"},{"key":"23_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809","volume":"56","author":"R von Rotz","year":"2023","unstructured":"von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K et al (2023) Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine 56:101809","journal-title":"EClinicalMedicine"},{"key":"23_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2022.100493","volume":"17","author":"TL Wallace","year":"2022","unstructured":"Wallace TL, Martin WJ, Arnsten AFT (2022) Kappa opioid receptor antagonism protects working memory performance from mild stress exposure in Rhesus macaques. Neurobiol Stress 17:100493","journal-title":"Neurobiol Stress"},{"key":"23_CR144","first-page":"1","volume":"26","author":"Y Wei","year":"2021","unstructured":"Wei Y, Chang L, Hashimoto K (2021) Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry 26:1\u201315","journal-title":"Mol Psychiatry"},{"key":"23_CR145","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jad.2024.07.030","volume":"362","author":"S Wong","year":"2024","unstructured":"Wong S, Le GH, Vasudeva S, Teopiz KM, Phan L, Meshkat S et al (2024) Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: a systematic review. J Affect Disord 362:816\u2013827","journal-title":"J Affect Disord"},{"key":"23_CR146","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J (2020) Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA 323:844\u2013853","journal-title":"JAMA"},{"key":"23_CR147","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.drudis.2021.02.011","volume":"26","author":"J Xiong","year":"2021","unstructured":"Xiong J, Xiong Z, Chen K, Jiang H, Zheng M (2021) Graph neural networks for automated de novo drug design. Drug Discov Today 26:1382\u20131393","journal-title":"Drug Discov Today"},{"key":"23_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108269","volume":"178","author":"PS Yang","year":"2020","unstructured":"Yang PS, Peng HY, Lin TB, Hsieh MC, Lai CY, Lee AS et al (2020) NMDA receptor partial agonist GLYX-13 alleviates chronic stress-induced depression-like behavior through enhancement of AMPA receptor function in the periaqueductal gray. Neuropharmacology 178:108269","journal-title":"Neuropharmacology"},{"key":"23_CR149","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00213-020-05469-0","volume":"237","author":"Y Yao","year":"2020","unstructured":"Yao Y, Ju P, Liu H, Wu X, Niu Z, Zhu Y et al (2020) Ifenprodil rapidly ameliorates depressive-like behaviors, activates mTOR signaling and modulates proinflammatory cytokines in the hippocampus of CUMS rats. Psychopharmacology 237:1421\u20131433","journal-title":"Psychopharmacology"},{"key":"23_CR150","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3389\/fphar.2019.01325","volume":"10","author":"RJ Zeifman","year":"2019","unstructured":"Zeifman RJ, Palhano-Fontes F, Hallak J, Arcoverde E, Maia-Oliveira JP, Araujo DB (2019) The impact of ayahuasca on suicidality: results from a randomized controlled trial. Front Pharmacol 10:1325","journal-title":"Front Pharmacol"},{"key":"23_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107536","volume":"26","author":"J Zhang","year":"2023","unstructured":"Zhang J, Lu Y, Jia M, Bai Y, Sun L, Dong Z et al (2023) Kappa opioid receptor in nucleus accumbens regulates depressive-like behaviors following prolonged morphine withdrawal in mice. iScience 26:107536","journal-title":"iScience"}],"container-title":["Advances in Experimental Medicine and Biology","Understanding Depression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-95-6872-7_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:28:31Z","timestamp":1777242511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-95-6872-7_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9789819568710","9789819568727"],"references-count":149,"URL":"https:\/\/doi.org\/10.1007\/978-981-95-6872-7_23","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 April 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declare the following as potential competing interests. Giampaolo Perna has received funding from Cariplo Foundation. He has served as consultant for Medibio LtD and for Menarini Industrie Farmaceutiche Riunite Srl, has received speaker honorarium from Dr. Willmar Schwabe GmbH & Co KG, Lundbeck and Pfizer and has been member of the advisor board of Biogen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The author(s) declare that this manuscript does not include primary research with human participants.The author(s) declare that this manuscript does not include primary studies involving animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}